Skip to main content
Clinical Trials/NCT03736018
NCT03736018
Active, not recruiting
Not Applicable

A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration and Complications in Patients Who Had Previous Bypass Operation Undergoing Invasive Coronary Angiography

Queen Mary University of London1 site in 1 country688 target enrollmentNovember 15, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischaemic Heart Disease
Sponsor
Queen Mary University of London
Enrollment
688
Locations
1
Primary Endpoint
Procedural duration
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

A large number of patients with symptomatic ischaemic heart disease undergo coronary artery bypass grafting (CABG) to alleviate their symptoms and improve prognosis. Given the progressive nature of coronary disease, bypass grafts can narrow or block over time, leading to chest pain and the need for further invasive coronary angiography. Invasive coronary procedures in patients with bypass grafts can be more complicated due to the variation in bypass graft ostia. This can lead to longer procedure times, with higher doses of contrast and radiation and more discomfort for the patient. The aim of this study is to see if the use of computed tomography cardiac angiography (CTCA) in patients with previous bypass grafts prior to invasive coronary angiography will help make their procedure safer and quicker.

Detailed Description

The BYPASS-CTCA trial is a single-centre, randomised controlled trial, which plans to recruit 688 patients who have had previous bypass grafts and require invasive coronary angiography over a period of 30 months. Patients will be randomised to receive either computed tomography cardiac angiography (CTCA) prior to their invasive coronary angiogram, or invasive coronary angiography alone. The primary endpoints will be the incidence of contrast induced nephropathy, the duration of the invasive coronary angiographic procedure and patient satisfaction. A number of secondary endpoints will also be looked at. Findings from BYPASS-CTCA will potentially demonstrate that a CTCA prior to invasive coronary angiography in this cohort of patients reduces the incidence of contrast-induced kidney injury, the length of procedure and improves patients satisfaction. The results of this trial may influence future clinical practice guidelines in coronary artery bypass graft patients undergoing invasive coronary procedures.

Registry
clinicaltrials.gov
Start Date
November 15, 2018
End Date
September 30, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing invasive coronary angiogram +/- percutaneous coronary Intervention
  • Previous Coronary Artery Bypass Grafting (CABG)
  • Patients able and willing to give their written informed consent.

Exclusion Criteria

  • Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation.
  • Subjects with eGFR \<20ml/min or on renal replacement therapy.
  • Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
  • Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications.
  • Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block
  • Known contrast dye allergy.
  • Pregnancy or unknown pregnancy status.
  • Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
  • Inability or refusal to provide informed consent.
  • Any inclusion criteria not met

Outcomes

Primary Outcomes

Procedural duration

Time Frame: Interval between administration of local anaesthesia for obtaining vascular access and removal of the last catheter

Length of invasive coronary angiogram

Incidence of Contrast Induced Nephropathy

Time Frame: 48-72hours

Defined by Kidney Disease: Improving Global outcomes (KDIGO) criteria

Patient satisfaction

Time Frame: 4-6hours

Patient satisfaction measured by validated questionnaire

Secondary Outcomes

  • Radiation exposure(From time of arterial sheath insertion to removal of arterial catheters)
  • Radial access rate(From time of randomisation to end of invasive coronary angiogram procedure)
  • Contrast amount(From time of arterial sheath insertion to removal of arterial catheters)
  • Angiography related complications(4-6hours)
  • Catheters used(From time of arterial sheath insertion to removal of arterial catheters)
  • Computed Tomography Cardiac Angiography accuracy(From time of randomisation to end of invasive coronary angiogram procedure)
  • Number of grafts not identified(From time of arterial sheath insertion to removal of arterial catheters)
  • Cost effectiveness of computed tomography cardiac angiography(12 months)

Study Sites (1)

Loading locations...

Similar Trials